Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Doug Heuring who wrote (847)	4/23/1998 4:43:00 PM
From: TheGoodDoctor	Read Replies (1) \| Respond to of 1432

Doug, BioTime applied for an expedited review process. The FDA will let BioTime know whether or not they will get an expedited or "fast-track" processing within two months (60 days) from the time the NDA (New Drug Application) was submitted. Since BioTime submitted the NDA at the end of March they/we should know by the end of May or beginning of June. If they are approved for an expedited review then the decision regarding approval (or not) of Hextend will occur within six months. If BioTime does not get an expedited review, then the review process may take up to eighteen months. At this point there's no way to predict what will happen - the longs and the shorts on this stock have already made their points pro and con - all we can do is wait. TheGoodDoctor